



 Panacea Biotech <i>Innovation in support of life</i>	Statement of unaudited financial results for the quarter ended June 30th,2012			
	(Rs. in Lacs)			
Particulars	For quarter ended		For year ended	
	30.6.2012	31.3.2012	30.6.2011	31.3.2012
	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
PART - I				
1. Income from operations				
a. Net sales / income from operations (net of excise duty)	8,310	8,998	22,099	68,838
b. Other operating income	558	97	470	1,220
Total income from operations (net)	8,868	9,095	22,569	70,058
2. Expenditure				
a. Cost of materials consumed	1,909	1,191	14,586	30,239
b. Purchase of stock in trade	508	512	607	2,452
c. Change in inventories of finished goods, work in progress and stock-in-trade	567	2,545	(6,549)	2,056
d. Employees benefits expense	3,437	3,467	3,663	15,045
e. Depreciation and amortisation expense	2,000	1,967	1,632	7,539
f. Manufacturing and administrative expenses	2,321	2,521	2,038	9,187
g. Other expenses	1,992	6,089	2,920	15,786
Total expenses	12,734	18,292	18,897	82,304
3. (Loss)/Profit from operations before other income, finance cost, foreign exchange fluctuation gain/ (loss) & exceptional items (1-2)	(3,866)	(9,197)	3,672	(12,246)
4. Other income	12	280	167	746
5. (Loss)/Profit from ordinary activities before finance cost, foreign exchange fluctuation gain / (loss) & exceptional items (3+4)	(3,854)	(8,917)	3,839	(11,500)
6. Finance cost	2,751	2,545	2,113	9,539
7. Foreign exchange fluctuation loss/ (gain)	1,371	1,320	(346)	1,041
8. (Loss)/Profit from ordinary activities after finance cost before exceptional items (5-6-7)	(7,976)	(12,782)	2,072	(22,080)
9. Exceptional items (refer note 7)	-	(4,214)	-	(4,214)
10. Profit / (loss) from ordinary activities before tax (8+9)	(7,976)	(16,996)	2,072	(26,294)
11. Tax expenses	(1,379)	(5,081)	400	(5,516)
12. Net profit / (loss) from ordinary activities after tax (10-11)	(6,597)	(11,915)	1,672	(20,778)
13. Extraordinary items (net of tax expenses)	-	-	-	-
14. Net profit / (loss) for the period (12-13)	(6,597)	(11,915)	1,672	(20,778)
15. Paid up equity share capital (face value of Re.1 per share)	613	613	613	613
16. Reserves excluding revaluation reserves				42,285
17. Earning per share (EPS) - Basic (in Rs.)	(10.77)	(19.46)	2.73	(33.92)
- Diluted (in Rs.)	(10.77)	(19.46)	2.73	(33.92)
PART - II				
A. Particulars of shareholding				
1. Public shareholding				
- No. of shares	15,426,992	15,427,192	15,369,872	15,427,192
- Percentage of shareholding	25.19	25.19	25.09	25.19
2. Promoters and promoter group Shareholding				
a) Pledge / encumbered				
- No. of shares	-	-	38,000	-
- % of Shares (as a % of the total shareholding of promoter & promoter group)	-	-	0.08	-
- % of Shares (as a % of the total share capital of the Company)	-	-	0.06	-
b) Non-encumbered				
- Number of shares	45,823,754	45,823,554	45,842,874	45,823,554
- % of Shares (as a % of the total shareholding of promoter & promoter group)	100.00	100.00	99.92	100.00
- % of Shares (as a % of the total share capital of the Company)	74.81	74.81	74.85	74.81



B. Investor complaints	
Pending at the beginning of the quarter	-
Received during the quarter	1
Disposed of during the quarter	1
Remaining unresolved at the end of the quarter	-

Unaudited Segment-wise Revenue , Results, and Capital Employed

Particulars	For quarter ended			For year ended
	30.6.2012 (Unaudited)	31.3.2012 (Unaudited)	30.6.2011 (Unaudited)	31.3.2012 (Audited)
1. Segment revenue				
(a) Vaccines	593	2,302	13,643	35,907
(b) Formulations	8,176	6,738	8,618	33,352
(c) Research & development	-	-	-	-
(d) Unallocated	99	55	308	799
Gross sale/Income from operation	8,868	9,095	22,569	70,058
Less : Inter segment revenue	-	-	-	-
Net sales/Income from operations	8,868	9,095	22,569	70,058
2. Segment results				
Profit (+)/ loss (-) before tax and interest from each segment				
(a) Vaccines	(2,274)	(2,061)	4,924	944
(b) Formulations	2,002	(263)	2,391	6,391
(c) Research & development	(1,767)	(4,170)	(1,710)	(10,414)
(d) Unallocated	-	-	-	-
Total	(2,039)	(6,494)	5,605	(3,079)
Less : i) Finance cost	2,751	4,804	1,631	9,539
ii) Other un-allocated expenditure net off un-allocated income	3,186	5,698	1,902	13,676
Total profit before tax	(7,976)	(16,996)	2,072	(26,294)
3. Capital Employed				
(Segment assets-segment liabilities)				
(a) Vaccines	72,374	74,570	75,089	74,570
(b) Formulations	30,370	28,384	18,991	28,384
(c) Research & development	24,411	23,666	20,990	23,666
(d) Unallocated	(52,820)	(45,420)	(49,719)	(45,420)
Total capital employed	74,335	81,200	65,351	81,200



Handwritten signature

1

- New Delhi
August 7, 2012
Panacea Biotech Limited

Dr. Rajesh Jain
Joint Managing Director

Regd. Office : Ambala-Chandigarh Highway, Lalru- 140501, Punjab
<http://www.panacea-biotec.com>

